In Other Journals

Ann Gregory
Med J Aust 2005; 182 (7): . || doi: 10.5694/j.1326-5377.2005.tb06723.x
Published online: 4 April 2005

A non-invasive, point-of-care proteomic assay may find a role in diagnosing bladder cancer as a useful adjunct to cystoscopy, according to US researchers.1 In a series of 1331 patients at increased risk for bladder cancer, they compared the performance of a nuclear matrix protein (NMP22) urinary assay with that of voided urine cytology, against a reference standard of cystoscopy with biopsy. The NMP22 assay was positive in 44 of 79 patients with cancer, whereas cytology test results were positive in only 12 of 76 patients. Further, the proteomic assay detected four cancers that were not visualised during initial endoscopy.

  • Ann Gregory



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.